Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by venture009on Sep 13, 2024 12:55pm
342 Views
Post# 36222564

Accelerated Approval

Accelerated ApprovalThe best chance ONC has of receiving AA is if the Trump grouis elected. Trump/RF Kennedy have said they will suspend the 70% of the FD receives from BP. Most feel the FDA has been compromised because of their reliance on BP and as a result of this contribution there is absolutely no doubt that BP receives biased consideration on certain decisions. This will force the FDA to get back to what it was designed to be, unbiased. "If" a large pharma has/is considering acquiring ONC it wouldn't be of any benefit to them for an AA being awarded to ONC. I always remember beig told that the h&n fiasco was designed by the FDA and yet even with all their expertise they failed to include what the side effects of reo were when working - fever and nausea. Naturally when this occured oncologists thought the worse and removed their patients from the trial. Resulting in the loss of 1/3 of the population, therefore the trial failed. Food for thought.
<< Previous
Bullboard Posts
Next >>